| Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study F Raffi, A Rachlis, HJ Stellbrink, WD Hardy, C Torti, C Orkin, M Bloch, ... The Lancet 381 (9868), 735-743, 2013 | 655 | 2013 |
| Major clinical outcomes in antiretroviral therapy (ART)–naive participants and in those not receiving ART at baseline in the SMART study Strategies for Management of Antiretroviral Therapy (SMART) Study Group The Journal of infectious diseases 197 (8), 1133-1144, 2008 | 580 | 2008 |
| Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2 … P Cahn, JS Madero, JR Arribas, A Antinori, R Ortiz, AE Clarke, CC Hung, ... The Lancet 393 (10167), 143-155, 2019 | 412 | 2019 |
| Inferior Clinical Outcome of the CD4+ Cell Count–Guided Antiretroviral Treatment Interruption Strategy in the SMART Study: Role of CD4+ Cell Counts and HIV … Strategies for Management of Antiretroviral Therapy (SMART) Study Group The Journal of infectious diseases 197 (8), 1145-1155, 2008 | 258 | 2008 |
| The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml JR Arribas, A Horban, J Gerstoft, G Fätkenheuer, M Nelson, N Clumeck, ... Aids 24 (2), 223-230, 2010 | 229 | 2010 |
| Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority … JM Molina, K Squires, PE Sax, P Cahn, J Lombaard, E DeJesus, MT Lai, ... The lancet HIV 5 (5), e211-e220, 2018 | 221 | 2018 |
| Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study HJ Stellbrink, J Reynes, A Lazzarin, E Voronin, F Pulido, F Felizarta, ... Aids 27 (11), 1771-1778, 2013 | 221 | 2013 |
| Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical … JR Arribas, F Pulido, R Delgado, A Lorenzo, P Miralles, A Arranz, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 40 (3), 280-287, 2005 | 212 | 2005 |
| Sustained Virological response to interferon plus Ribavirin reduces non–liver-related mortality in patients Coinfected with HIV and hepatitis C virus J Berenguer, E Rodríguez, P Miralles, MA Von Wichmann, ... Clinical infectious diseases 55 (5), 728-736, 2012 | 201 | 2012 |
| Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos (t) ide reverse … JR Arribas, PM Girard, R Landman, J Pich, J Mallolas, ... The Lancet Infectious Diseases 15 (7), 785-792, 2015 | 194 | 2015 |
| Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV F Pulido, JR Arribas, R Delgado, E Cabrero, J González-García, ... Aids 22 (2), F1-F9, 2008 | 192 | 2008 |
| Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study D Podzamczer, E Ferrer, P Sanchez, JM Gatell, M Crespo, C Fisac, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 44 (2), 139-147, 2007 | 180 | 2007 |
| Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study J Reynes, R Trinh, F Pulido, R Soto-Malave, J Gathe, R Qaqish, M Tian, ... AIDS research and human retroviruses 29 (2), 256-265, 2013 | 173 | 2013 |
| 2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0 L Ryom, A Cotter, R De Miguel, C Béguelin, D Podlekareva, JR Arribas, ... HIV medicine 21 (10), 617-624, 2020 | 168 | 2020 |
| Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial SMART Study Group* Annals of internal medicine 149 (5), 289-299, 2008 | 165 | 2008 |
| Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B F Laguna, R López-Vélez, F Pulido, A Salas, J Torre-Cisneros, E Torres, ... Aids 13 (9), 1063-1069, 1999 | 155 | 1999 |
| Incidence of acquired immunodeficiency syndrome-associated opportunistic diseases and the effect of treatment on a cohort of 1115 patients infected with human immunodeficiency … FJ San-Andrés, R Rubio, J Castilla, F Pulido, G Palao, I de Pedro, ... Clinical infectious diseases 36 (9), 1177-1185, 2003 | 150 | 2003 |
| Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis JR Arribas, R Delgado, A Arranz, R Muñoz, J Portilla, J Pasquau, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 51 (2), 147-152, 2009 | 144 | 2009 |
| Genetic barrier to resistance for dolutegravir. JM Llibre, F Pulido, F García, M Garcia Deltoro, JL Blanco, R Delgado AIDS reviews 17 (1), 2015 | 142 | 2015 |
| Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis S Mathis, B Khanlari, F Pulido, M Schechter, E Negredo, M Nelson, ... PloS one 6 (7), e22003, 2011 | 140 | 2011 |
